Ongentys (Opicapone)

Opicapone, the active ingredient in Ongentys, is a catechol-O-methyltransferase (COMT) inhibitor presented as a tablet for oral use. It is used as an adjunct therapy to manage motor fluctuations in patients with Parkinson's disease who are experiencing wearing‑off phenomena while on levodopa/carbidopa treatment.

GNH USA supplies Ongentys as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ongentys is a COMT inhibitor that addresses motor complications associated with Parkinson's disease therapy. - Parkinson's disease (wearing‑off): Improves the duration of levodopa effect and reduces daily OFF time. - Adjunct to levodopa/carbidopa: Enhances overall motor control when added to standard Parkinson's regimens. - Motor fluctuations: Provides more consistent symptom control throughout the dosing interval.

Adverse reactions reported with Opicapone are generally mild to moderate and reflect its pharmacologic activity and formulation.

Common Side Effects: - Dyskinesia: Increased involuntary movements, especially when combined with levodopa. - Nausea: Mild to moderate gastrointestinal upset. - Diarrhea: Loose stools occurring shortly after dosing. - Dry mouth: Reduced salivation leading to oral discomfort. - Headache: Transient cranial pain. - Insomnia: Difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Orthostatic hypotension: Marked drop in blood pressure upon standing. - Hallucinations: Visual or auditory perceptual disturbances. - Severe constipation: Bowel obstruction risk. - Elevated liver enzymes: Indicating potential hepatic stress. - Allergic reactions: Rash, pruritus, or angio‑edema. - Neuroleptic malignant‑like syndrome: Rare but life‑threatening hyperthermic reaction.

When prescribing Opicapone, clinicians should consider several safety aspects. - Dose adjustment: Review levodopa dosage to avoid excessive dyskinesia. - Hepatic function: Monitor liver enzymes periodically, especially in patients with pre‑existing liver disease. - Cardiovascular status: Observe for signs of orthostatic hypotension. - Psychiatric history: Watch for emergence of hallucinations or confusion. - Renal impairment: Use caution in severe renal dysfunction. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Opicapone may alter the pharmacokinetics of several co‑administered medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: Increased risk of hypertensive crisis. - Tranylcypromine: Potentiates sympathomimetic effects leading to severe hypertension. - Certain antihypertensives: May exacerbate orthostatic hypotension when combined.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): May increase serotonergic activity. - Antipsychotics (Clozapine, Olanzapine): Potential for reduced dopaminergic efficacy. - Antidiabetic agents: May require dose adjustment due to altered glucose metabolism.